ARS Pharmaceuticals, Inc.
$8.18
▲
2.34%
2026-04-21 09:35:00
ars-pharma.com
NGM: SPRY
Explore ARS Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$812.25 M
Current Price
$8.18
52W High / Low
$18.9 / $6.66
Stock P/E
—
Book Value
$1.15
Dividend Yield
—
ROCE
-62.2%
ROE
-92.33%
Face Value
—
EPS
$-1.74
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
158
Beta
0.93
Debt / Equity
147.49
Current Ratio
7.28
Quick Ratio
7.06
Forward P/E
-11.14
Price / Sales
9.48
Enterprise Value
$722.87 M
EV / EBITDA
-4.06
EV / Revenue
8.58
Rating
Strong Buy
Target Price
$26.71
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alumis Inc. | $24.71 | — | $3.18 B | — | -134.01% | -86.68% | $30.6 / $2.76 | $2.88 |
| 2. | Invivyd, Inc. | $1.68 | — | $492.08 M | — | -22.89% | -33.97% | $3.07 / $0.46 | $0.86 |
| 3. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 4. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 5. | Iovance Biotherapeutics, Inc. | $3.78 | — | $1.56 B | — | -51.39% | -55.5% | $5.63 / $1.64 | $1.7 |
| 6. | Dianthus Therapeutics, Inc. | $91.92 | — | $5 B | — | -35.57% | -38.38% | $96.5 / $16.64 | $11.41 |
| 7. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 28.09 M | 32.5 M | 15.72 M | 7.97 M | 86.58 M | — |
| Operating Profit | -41.47 M | -53.19 M | -47.61 M | -37.18 M | 47.2 M | — |
| Net Profit | -41.32 M | -51.15 M | -44.88 M | -33.94 M | 49.93 M | — |
| EPS in Rs | -0.42 | -0.52 | -0.45 | -0.34 | 0.5 | -0.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 84.28 M | 89.15 M | 0.03 M | 1.32 M |
| Operating Profit | -179.45 M | -3.08 M | -67.52 M | -35.52 M |
| Net Profit | -171.3 M | 8 M | -54.37 M | -34.68 M |
| EPS in Rs | -1.73 | 0.08 | -0.55 | -0.35 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 327.65 M | 351.15 M | 233.19 M | 281.44 M |
| Total Liabilities | 213.39 M | 94.36 M | 2.43 M | 8.55 M |
| Equity | 114.26 M | 256.8 M | 230.76 M | 272.89 M |
| Current Assets | 284.9 M | 334.3 M | 231.73 M | 277.7 M |
| Current Liabilities | 39.15 M | 23.44 M | 2.39 M | 5.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -170.87 M | 13.55 M | -59.27 M | -40.08 M |
| Investing CF | 56.77 M | -106.1 M | -87.18 M | -0.2 M |
| Financing CF | 104.6 M | 72.4 M | 6.9 M | 190.73 M |
| Free CF | -171.21 M | 12.98 M | -59.44 M | -40.28 M |
| Capex | -0.34 M | -0.56 M | -0.17 M | -0.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 297063.33% | -97.72% | — | — |
| Earnings Growth % | 114.71% | -56.75% | — | — |
| Profit Margin % | 8.97% | -181216.67% | -2635.41% | — |
| Operating Margin % | -3.46% | -225066.67% | -2698.78% | — |
| Gross Margin % | 98.9% | 100% | — | — |
| EBITDA Margin % | 9.29% | -225066.67% | -2674.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.